Desmopressin (DDAVP), an arginine vasopressin analogue, markedly stimulates ACTH secretion in patients with Cushing's disease, in contrast to its minimal effect in normal subjects. However, little is known about the mechanisms underlying this action and it appeared to be of interest to evaluate the effect of DDAVP on ACTHsecreting pituitary adenomas in vitro, in comparison with its effect in the same patients in vivo. Pituitary adenomas from 14 patients with Cushing's disease were incubated with DDAVP, corticotrophin-releasing hormone (CRH) and DDAVP together with vasopressin receptor antagonists or CRH. Incubation with DDAVP induced a modest dose-dependent increase in ACTH concentrations which appeared maximal at 10 nM. CRH stimulated ACTH to a greater extent compared with DDAVP and potentiated the effect of DDAVP alone. The DDAVP-induced ACTH increase appeared blunted by vasopressin V 2 and V 3 receptor antagonists. V 3 receptor gene expression was detected by RT-PCR in all adenoma samples except for two which were not responsive to DDAVP in vitro but responsive to the peptide in vivo. Surprisingly, no difference in the in vitro ACTH secretory response was observed between in vivo DDAVP-responsive (ACTH peak>150% baseline) and -unresponsive (ACTH peak<120% baseline) patients, suggesting that the pituitary adenoma is not the sole mediator of the ACTH-releasing effect of DDAVP. In conclusion, the marked stimulatory effect of DDAVP observed in patients with Cushing's disease appears to be mainly dependent on an extrapituitary action, possibly the inhibition of a corticotrophin release-inhibitory factor.
Introduction
Desmopressin (DDAVP), the long-acting analogue of arginine vasopressin (AVP), has recently been shown to markedly stimulate corticotrophin (ACTH) and cortisol secretion in patients with Cushing's disease (Malerbi et al. 1993 , Colombo et al. 1997 , Sakai et al. 1997 , Moro et al. 2000 . This behaviour is typical for patients with an ACTH-secreting pituitary tumour as DDAVP exerts only a modest stimulatory effect in normal subjects (Andersson et al. 1972 , Gaillard et al. 1988 ) and in patients with pseudoCushing syndrome (i.e. patients with alcoholism, obesity and depression, presenting clinical and/or biochemical features resembling Cushing's disease) (Malerbi et al. 1996 , Tsagarakis et al. 1999 , Coiro et al. 2000 , Moro et al. 2000 . On the basis of this evidence, we recently recommended the use of DDAVP in the differential diagnosis between mild forms of Cushing's disease and pseudoCushing syndrome (Moro et al. 2000) .
The mechanisms whereby DDAVP selectively stimulates ACTH secretion in patients with Cushing's disease are not yet fully understood. DDAVP is a known agonist for the V 2 receptor (i.e. kidney receptor) but has also been shown to bind the V 3 receptor isoform (Thibonnier et al. 1998) . This latter is a characteristic of ACTH-secreting cells, both within and without the pituitary (Lolait et al. 1995 , De Keyzer et al. 1996 , and is apparently overexpressed in tumoural corticotrophs (Dahia et al. 1996 , De Keyzer et al. 1998 , thus possibly subserving the marked response to DDAVP observed in patients with Cushing's disease.
The aim of the present study was to evaluate the response to DDAVP in pituitary ACTH-secreting adenomas in vitro, in comparison with the response observed in vivo in the same patients prior to surgery. In addition, we investigated the AVP receptor subtype involved in this response by performing co-incubation experiments with DDAVP and AVP receptor antagonists and by evaluating V 3 receptor mRNA in individual tumour cultures. Lastly, the effect of DDAVP on ACTH was compared with the selfsame response to corticotrophin-releasing hormone (CRH), alone and together with DDAVP itself.
Materials and Methods

Patients
Fourteen patients with an ACTH-secreting pituitary adenoma (eleven females and three males; age 40·0 3·39 years, range 20-68) were studied. Diagnosis of Cushing's disease was established by standard criteria (Invitti et al. 1999a) , including stimulation with CRH in six patients, and confirmed by results of pituitary pathology. Tumour size was greater than 1 cm in patients 1, 2, 4, 9-11 and 13, the remainder presenting a microadenoma (size range 6-9 mm).
In vivo studies
Preoperative testing with DDAVP was performed as previously described (Moro et al. 2000) . In short, DDAVP (10 µg; Minirin, Ferring Pharmaceuticals Ltd, Malmo, Sweden) was injected in the morning after an overnight fast and serum samples were collected prior to and 15, 30, 45, 60, 90 and 120 min after the injection. Plasma ACTH levels were measured by immunoradiometric assay (Nichols Institute, San Juan Capistrano, CA, USA). In our laboratory, intra-and interassay coefficients of variation are 3·2 and 8·2% respectively. In order to clearly differentiate DDAVP-responsive and -unresponsive patients we adopted stringent response criteria: a peak increase in ACTH levels greater than 150% of baseline identified responders whereas an ACTH peak less than 120% of baseline identified non-responders. These separate cut-offs were purposely chosen to allow a clear characterization of the in vivo DDAVP response pattern.
In vitro studies
ACTH-secreting pituitary adenomas were collected during trans-sphenoidal surgery and established in culture according to our usual protocol (Invitti et al. 1999b) . Briefly, adenomas were enzymatically dispersed, checked for viability, plated at a density of 2 10 5 cells/well, and incubated in Dulbecco's modified Eagle's medium (DMEM), 10% fetal calf serum and antibiotics for 3-5 days. The following treatments were performed according to the abundance of the tumour specimen: (1) 1 nM-10 µM DDAVP, (2) 10 nM CRH, (3) 10 nM CRH and 10 nM-1 µM DDAVP together, (4) 10 µM V 1 receptor antagonist ((3-(4-azidophenyl) ACTH was measured by radioimmunoassay (Pecori Giraldi & Cavagnini 1998) after 1-and 4-h incubations with test agents. Sensitivity, intra-and interassay coefficients of variation of this assay are 0·5 pg/ml, 5·9% and 6·8% respectively.
Total RNA was extracted from pituitary adenoma primary cultures using RNAzol B (Tel Test Inc., Friendswood, TX, USA). RNA was reverse transcribed in the presence of 0·5 mM deoxynucleoside triphosphate, 10 µM random primers, 25 U RNase inhibitor and 200 U murine leukaemia virus reverse transcriptase for 45 min at 37 C. The resulting cDNA was amplified with 500 nM intron-spanning primers specific to the human V 3 receptor gene (upstream: bp 2420-2440, downstream bp 8185-8205; Genebank Accession #AF152238) and Taq DNA polymerase according to the following protocol: initial denaturing at 95 C for 2 min, then 95 C for 20 s, 60 C for 20 s and 72 C for 30 s for 35 cycles, followed by a 5-min extension at 72 C. The identity of the V 3 receptor PCR product was confirmed by Southern blotting with a digoxigenin-labelled oligonucleotide (bp 7871-7892 of the human V 3 receptor gene) according to the manufacturer's instructions (DIG oligonucleotide tailing kit; Boehringer Mannheim GmbH, Mannheim, Germany). RNA from a growth hormone-secreting adenoma was used as a negative control. The integrity of RNA was assessed by amplification of the hypoxanthine phosphoribosyltransferase (HPRT) gene with 250 nM intronspanning primers (upstream: bp 570-589, downstream: bp 647-667; Genebank Accession #NM000194) according to the same PCR protocol except for annealing at 53 C. Reagents for reverse transcription, PCR and restriction enzyme digestion were provided by Promega Corp., Madison, WI, USA.
For statistical analysis, experiments were normalized as a percentage of control and treatments were compared using Wilcoxon's statistic for non-parametric data. Qualitative data were analysed by the chi square statistic. Data are expressed as means S.E.M. Statistical significance was accepted at P<0·05.
Results
Testing with DDAVP in vivo identified nine patients (2, 3, 5-7, 9-11 and 14) in whom DDAVP induced a clear ACTH increase (peak>150% baseline) and five nonresponsive patients (1, 4, 8, 12 and 13) , as may occur in some patients with Cushing's disease (Moro et al. 2000) . There was no difference between these two groups as regards age, size of the adenoma at pituitary imaging, and basal ACTH levels. ordered according to the strength of the in vitro ACTH response with patient 1 presenting the lowest and patient 14 the greatest response. As can be seen, the stimulatory effect of DDAVP, if present, was already apparent after 1 h of incubation; by 4 h of incubation this increase in ACTH concentration was further magnified. The stimulatory effect of DDAVP appeared to be dose-dependent (maximal stimulation at 10 nM; Fig. 2 ) and slightly, although not significantly, greater in micro-than in macroadenomas (maximal ACTH increase at 1 h: 190·9 34·37 vs 164·8 25·58% of control, not significant (NS) and at 4 h: 174·2 21·10 vs 150·8 20·18% of control, NS respectively). Surprisingly, no response could be observed in cultures from patients 2, 3, 5 and 6 in whom DDAVP had elicited a marked increase in ACTH levels in vivo (Fig. 1) . Further, there appeared to be no correlation between the in vivo and in vitro DDAVP responsiveness as a clear-cut increase in ACTH concentrations (i.e. peak at least 50% higher than control secretion) was observed in five out of nine DDAVP responders (patients 7, 9-11 and 14) and three out of five DDAVP non-responders (patients 8, 12 and 13). Overall, no difference could be detected in the mean DDAVPinduced ACTH increase between in vivo DDAVP responders and non-responders (Fig. 2) . All tumours incubated with CRH released substantial amounts of ACTH and a comparison of DDAVP and CRH responses in individual tumour cultures showed that ACTH concentrations after DDAVP were mostly smaller than those after CRH, except for patient 14 (Fig. 1) ; this difference was already apparent 1 h after incubation with the test agent. Overall, the mean DDAVP-induced increase was clearly smaller than the mean CRH-evoked response (Fig. 2) whereas, in the same patients, the peak ACTH response to the two stimuli was comparable in vivo (483·9 179·15% vs 344·8 135·82% of baseline, NS for DDAVP and CRH respectively). The effect of CRH incubation in vitro could be compared with the ACTH response to CRH prior to surgery in patients 1, 3, 7, 10, 12 and 14. All these patients were responsive to CRH in vivo (peak ACTH ranging from 161% to 1267% of baseline) and their tumours gave rise to a secretory response to CRH in vitro (Fig. 1) .
Incubation of DDAVP and CRH together was performed in five pituitary adenomas (patients 4 and 9-12). In all experiments, co-incubation with CRH increased the DDAVP-induced ACTH response, even in the one patient who was unresponsive to DDAVP alone (patient 4). ACTH concentrations during incubation with DDAVP+CRH were significantly higher than with DDAVP alone but not different from those with CRH alone (Fig. 3) , thus showing that CRH strongly increases the ACTH response to DDAVP but the latter only slightly enhances the ACTH response to CRH. Incubation with AVP receptor antagonists was performed in seven tumour cultures (patients 1-3, 6-8 and 14) and did not affect ACTH concentrations (all NS). Co-incubation of DDAVP and V 2 or V 3 receptor antagonists in three tumours responsive to DDAVP in vitro (patients 7, 8 and 14) blunted the ACTH increase, although this effect did not reach statistical significance (P=0·062 for V 2 and P=0·057 for V 3 ; Fig. 4) . No clear-cut change in ACTH medium concentrations was observed during co-incubation with the V 1 receptor antagonist (NS; Fig. 4) .
V 3 receptor gene expression was detected in most patients, regardless of their in vivo response status (data not shown); tumour mRNA tested positive for V 3 receptor in all cultures in which DDAVP stimulated ACTH in vitro (patients 7-14) and also in some specimens unresponsive to DDAVP in vitro (patients 1-4). The integrity of mRNA in tumour cultures which failed to express the V 3 gene was established by positive amplification of the HPRT gene. The small amount of RNA obtained from each sample did not allow us to seek evidence for V 2 receptor gene expression.
Discussion
Recent years have seen a renewed interest in the action of DDAVP, a V 2 receptor agonist, on ACTH secretion. In fact, evidence collected by us and others has demonstrated that most patients with Cushing's disease present a marked increase in plasma ACTH levels following i.v. administration of DDAVP (Malerbi et al. 1993 , Colombo et al. 1997 , Sakai et al. 1997 , Moro et al. 2000 , in contrast with the barely detectable response observed in normal subjects (Andersson et al. 1972 , Gaillard et al. 1988 and patients with pseudoCushing syndrome (Malerbi et al. 1996 , Tsagarakis et al. 1999 , Coiro et al. 2000 , Moro et al. 2000 . On the basis of mRNA quantification studies, it had been hypothesized that the hyper-response observed in patients with Cushing's disease was due to an overexpression of the pituitary AVP receptor subtype (i.e. V 3 ) by the ACTHsecreting pituitary adenoma (Dahia et al. 1996 , De Keyzer et al. 1998 . This hypothesis relied on the fact that DDAVP, while presenting high affinity for the V 2 receptor subtype (K i 2·7 nM), also interacts with the V 3 receptor (K i 22 nM) (Thibonnier et al. 1998 ) and thus could directly stimulate adenomatous corticotrophs.
To our knowledge, only one study has been published reporting the effect of DDAVP on primary cultures from ACTH-secreting pituitary adenomas (Sakai et al. 1997) . In this series of three adenomas, DDAVP induced a variable increase in ACTH concentrations, overall far less than the release evoked by CRH. The authors concluded that DDAVP directly stimulates ACTH secretion by tumoural corticotrophs, although no comparison with the in vivo response to DDAVP was performed (Sakai et al. 1997 ). An additional recent case report described a stimulatory effect of 100 nM DDAVP on long-term cultures from an ACTH-secreting macroadenoma (Abe et al. 2000) .
The evidence collected in our larger series of experiments indicates that DDAVP exerts only a modest stimulatory effect (barely 1·5-fold) on ACTH-secreting pituitary adenomas in vitro. Surprisingly, the response to DDAVP in vitro was of modest magnitude even in patients exhibiting an ACTH increase over 200% of baseline in response to DDAVP in vivo. Indeed, incubation with DDAVP did not elicit a greater ACTH increase in adenomas from patients responsive to DDAVP compared with adenomas excised from DDAVP non-responsive patients. These data suggest a dissociation of the in vitro and in vivo ACTH responsiveness to DDAVP.
By comparison, CRH induced a far greater increase in ACTH concentrations in all but one specimen and this disparity is noteworthy given the fact that, in vivo, CRH and DDAVP elicit largely comparable ACTH increases in patients with Cushing's disease, both in terms of peak and timing of the ACTH response (Sakai et al. 1997 , Putignano et al. 1999 . Results of co-incubation experiments indicate that CRH and DDAVP exert additive effects on ACTH release in vitro.
It is worth recalling that the ACTH increase elicited by DDAVP in patients with Cushing's disease was unique to the analogue and distinct from the ACTH-stimulatory effect of AVP, the parent peptide. In fact, the stimulatory effect of AVP in patients with an ACTH-secreting pituitary adenoma is markedly smaller than the response of the same subjects to CRH (Liu et al. 1983 , Catania et al. 1984 , Dickstein et al. 1996 , Sakai et al. 1997 . Further, in vitro data from rat pituitary primary cultures demonstrated a different ACTH responsiveness to AVP and DDAVP ( Antoni 1984 , Knepel et al. 1984 , Buckingham 1987 . Evidently, DDAVP and AVP do not appear to act in the same manner on both tumoural and non-tumoural corticotrophs.
Our incubation data point towards both V 2 and V 3 receptor subtypes subserving the effect of DDAVP on tumoural corticotrophs. Either receptor antagonist in fact blunted the DDAVP-induced ACTH release in vitro, an observation in keeping with the expression of both receptors in tumoural corticotrophs (Dahia et al. 1996) . The faint response to DDAVP per se and the involvement of both receptors may have hampered the attainment of statistical significance for individual receptor antagonists alone. In our hands, V 3 receptor gene expression was detected in all tumours which exhibited a response to DDAVP in vitro as well as in primary cultures which did not respond to DDAVP. V 3 receptor mRNA was not detected in two specimens, both from patients in whom DDAVP failed to stimulate ACTH secretion in vitro but were clearly responsive to DDAVP in vivo.
The direct comparison of corticotroph secretory activity in vivo and in vitro may be biased by the inherent diversity of the two experimental conditions and the possible problems related to tumour explantation and culture, such as cell damage, loss of receptor and heterogeneity of the excised specimen. In our hands, the maintained responsiveness of cultured corticotrophs to CRH, for which there was a complete concordance between in vivo and in vitro stimulation, argues against a possible receptor loss or damage to the secretory apparatus during tumour isolation. Further, CRH responsiveness indicates the presence of adenomatous corticotrophs as neighbouring, normal corticotrophs are suppressed and unresponsive to CRH (Avgerinos et al. 1987 , Invitti et al. 1999a ). In addition, corticotroph secretory capacity was by no means exhausted by DDAVP, as indicated by the fact that CRH alone or with DDAVP was capable of inducing a significantly greater ACTH release. Therefore, even using appropriate circumspection while translating in vivo findings to in vitro conditions, our findings showed a superimposable in vitro ACTH response to DDAVP in patients who presented a clearly different response pattern in vivo. Evidently, the removal of the tumoural corticotroph from its milieu interfered with DDAVP responsiveness and some factor other than the direct stimulatory action of DDAVP on adenomatous corticotrophs must contribute to in vivo responsiveness. In this context, several scenarios can be drawn.
Theoretically, DDAVP could act at the hypothalamic level in order to stimulate CRH, as occurs for AVP (Hedge et al. 1966 , Kjaer et al. 1992 . This hypothesis, however, is not unchallenged as other investigators have reported findings suggesting an inhibitory circuit from AVP to CRH (Plotsky et al. 1984) . Further, normal subjects fail to respond to DDAVP in vivo and thus it is unlikely that CRH mediates the marked DDAVP-induced increase in patients with Cushing's disease.
In an alternative hypothesis, DDAVP could act through the blunting of an endogenous inhibitor of ACTH secretion. The existence of a non-corticosteroid inhibitor of ACTH secretion has long been postulated and was recently reviewed (Engler et al. 1999 , Jessop 1999 . Several candidate corticotrophin-release inhibitory factors (CRIF), have been studied, such as preprothyrotrophinreleasing hormone , atrial natriuretic peptide, dopamine, lipocortin and endogenous opioids, to list but a few, although conclusive evidence for one of these factors is as yet lacking. Even oxytocin, the 'sister' neurohormone to AVP, has been postulated to inhibit ACTH secretion (Legros 2001) . In view of the existence of a corticotrophin-release inhibitory tone, it stands to reason that this system might be hyperactivated in Cushing's disease. DDAVP might interfere with this inhibitor and thus cause ACTH release, much as it occurs for dopamine antagonists in hyperprolactinaemia.
In conclusion, the present study has demonstrated a discrepancy between the ACTH response to DDAVP observed in vivo in patients with Cushing's disease and the effect of DDAVP on pituitary adenoma cultures from the same patients. Our findings support the view that the bulk of the ACTH response triggered by DDAVP in patients with Cushing's disease is due to an extrapituitary mechanism, possibly inhibition of the fabled CRIF.
